A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer

Pasi A Jänne ¹, David Planchard ^2,3, Kunihiko Kobayashi ⁴

¹aDepartment of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
²bDepartment of Medical Oncology, Thoracic Group and International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France.
³cFaculty of Medicine, Paris-Saclay University, Paris, France.
⁴dDepartment of Respiratory Medicine, Saitama Medical University, International Medical Center, Hidaka, Japan.
⁵eDepartment of Thoracic Oncology, Jilin Cancer Hospital, Changchun, China.
⁶fDepartment of Medical Oncology, Cancer Care Centre, St. George Hospital, Kogarah, NSW, Australia.
⁷gDepartment of Oncology, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
⁸hFederal State Budgetary Institution "N.N.Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation, Moscow, Russia.
⁹iDivision of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
¹⁰jDepartment of Life Sciences, National Chung Hsing University, Taichung, Taiwan.
¹¹kDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
¹²lDepartment of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
¹³mDepartment of Respiratory Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
¹⁴nDivision of Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
¹⁵oDepartment of Internal Medicine, Prince of Songkla University, Songkhla, Thailand.
¹⁶pDepartment of Clinical Oncology, Rondebosch Oncology Centre, Rondebosch, Cape Town, South Africa.
¹⁷qMedical Oncology Department, Bradford Hill Clinical Research Center, Santiago, Chile.
¹⁸rDivision of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
¹⁹sDepartment of Medical Oncology and Hematology, University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada.
²⁰tResearch Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
²¹uLate-stage Development, Oncology Research and Development, AstraZeneca, Cambridge, United Kingdom.
²²vLate-stage Development, Oncology Research and Development, AstraZeneca, Gaithersburg, MD, USA.
²³wBiometrics, Late-stage Development, Oncology Research and Development, AstraZeneca, Cambridge, UK.
²⁴xDepartment of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.

⁰aDepartment of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Future Oncology +

|

March 7, 2025

Summary

No abstract available on PubMed